Business Context and Reporting Period
This Form 8-K Current Report was filed by MRI Interventions, Inc. on December 18, 2014. The filing discloses the entry into a Material Definitive Agreement for a private placement financing transaction. The company anticipates closing the transaction on or before December 24, 2014.
Key Financial Metrics and Transaction Details
The filing details a Financing Transaction involving the sale of common stock and warrants to accredited investors. Key terms include:
- Gross Proceeds: Approximately $10.2 million.
- Securities Issued: Approximately 15.8 million shares of common stock and warrants to purchase approximately 6.3 million shares.
- Purchase Price: $0.6435 per unit (one share plus one warrant).
- Warrant Exercise Price: $0.858 per share.
- Warrant Term: Five years from issuance.
- Placement Agent: Brookline Group, LLC, receiving cash commissions and Placement Agent Warrants.
The filing does not provide current revenue, profit, cash flow, margin, or debt figures; it focuses exclusively on the capital raise.
Material Changes and Agreements
The primary material change is the execution of a Securities Purchase Agreement and a Registration Rights Agreement. Under the Registration Rights Agreement, the Company must file a registration statement with the SEC within 30 calendar days of closing to cover the resale of the issued securities. Failure to file or have the statement declared effective within specified timelines (75 or 120 days) will result in liquidated damages payable to investors.
Outlook, Risks, and Unusual Items
Outlook and Management Commentary: Management anticipates closing the transaction by December 24, 2014, subject to customary closing conditions. The proceeds are intended to support the company's operations, though specific allocation is not detailed in this text.
Risks and Contingencies:
- Closing Risk: There is no assurance the transaction will close on the described terms or in a timely manner.
- Registration Risk: The company faces potential liquidated damages if SEC registration requirements are not met within the agreed deadlines.
- Dilution: The issuance of 15.8 million shares and warrants for 6.3 million shares represents significant potential dilution to existing shareholders.
- Warrant Redemption: Investor Warrants are redeemable if the stock price exceeds twice the exercise price ($1.716) for 20 consecutive trading days; Placement Agent Warrants are not redeemable.
Investor Verification Checklist
- Verify the actual closing date and final gross proceeds received.
- Confirm the filing and effectiveness date of the required SEC Registration Statement.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and indemnification terms.
- Assess the impact of the 15.8 million new shares and 6.3 million warrant shares on existing shareholder ownership percentages.
- Monitor the stock price relative to the $1.716 redemption threshold for Investor Warrants.